Colonics
About Me
Recent Posts
- Protein Protects Against Breast Cancer Recurrence In Animal Model
- Light-Carved 'Nano-Volcanoes' Hold Promise For Drug Delivery
- Older People May Be Protected From Influenza By Their Saliva
- New Array Measures Vibrations Across The Skin, May Help Engineers Design Optimal, Wearable Tactile Displays
- Protect Medical Devices From Cyber Attacks, FDA Urges
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
Friends
Links
Entry 1 of 2709
Last Page | Next Page
3/5/2010
-
Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients
|
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the instance of venous thromboembolism in clients undergoing elective total knee stand-in surgery, according to rule to rule to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically homogeneity non-major softy in llc.cite this source roget's ii: the new thesaurus treated with apixaban compared with those treated with enoxaparin. More: - The rest... |
:: Send to a Friend! |
Share and enjoy
Report this!